Your generous year-end donation will be matched $1 for $1 DONATE
NCCS recently submitted a comment letter to the Centers for Medicare and Medicaid (CMS) regarding the Medicare physician fee schedule for calendar year 2021. The comment letter focuses on telehealth-related provisions of the proposed rule, as we are learning from our findings from our Telehealth Project that both patients and providers need more tools and […]
NCCS joined with other cancer patient and provider groups in a comment letter to the Centers for Medicare and Medicaid Services (CMS) regarding the proposed rule related to the hospital outpatient prospective payment system. Among the issues outlined in the letter is a concern about an additional reduction in payment for drugs in the 340B […]
NCCS joined with a group of patient and provider advocacy groups in a letter to the National Academy of Medicine (NAM) on vaccine allocation. In the letter, the groups articulate the substantial risk that cancer patients face during the pandemic and shared data on the negative outcomes of patients with cancer and concurrent COVID-19. The […]
The National Coalition for Cancer Survivorship (NCCS) submitted comments in response to an Informal Request for Information on the proposed Oncology Care First Model. This model was released by the Centers for Medicare and Medicaid Services (CMS). The comments focus on concerns regarding adequate resources in the model to support high quality cancer care. The letter also identifies shortcomings in the model that could influence […]
The National Coalition for Cancer Survivorship (NCCS) joined with AARP and 47 other organizations in letters to the House and Senate asking Members to co-sponsor the Medical Expense Savings Act, which is bipartisan legislation that would make permanent the 7.5 percent threshold for the medical expense deduction. This deduction provides an important tax relief for many patients which helps offset the high costs of cancer care. […]
NCCS joined with public health and medical organizations in a comment letter to the U.S. Food and Drug Administration (FDA) regarding the proposed rule to establish health warnings for cigarette packages and advertisements. The comment letter outlines the overwhelming evidence that shows color graphic health warnings on cigarette packages and ads substantially increases and promotes greater public understanding of the dangers of smoking, […]
NCCS and member organizations of the Cancer Leadership Council (CLC) submitted comments to the HHS in response to the agency’s Notice of Benefits and Payment Parameters for 2020. The Notice contains rules and provisions that will apply to the individual market (the Affordable Care Act marketplace), and small group health insurance markets. The letter states NCCS’ concerns about specific provisions that may threaten cancer patients’ access […]
The Department of Health and Human Services (HHS) released recently a proposed rule to change Medicare Part D’s protected classes drug coverage. In response, NCCS joined with other patient and provider groups of the Cancer Leadership Council (CLC) to comment on how these proposed changes could impact patients. The proposed rule would give Medicare plans the option to limit coverage of drugs in six categories, including cancer drugs. […]
On December 31st, NCCS submitted our final comment letter of the year to the Centers for Medicare and Medicaid Services regarding the advance notice of proposed rulemaking for the Medicare Part B drug program.
In the letter, we outlined concerns that this proposal could have on Medicare beneficiaries such as impacts on patient access to innovative therapies, as well as concerns regarding the enormous scope of the test. NCCS suggested […]
Earlier this year, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule that would require information about drug costs be included in direct-to-consumer (DTC) advertisements of prescription drugs and biological products. NCCS issued a statement regarding the proposal, saying, “While we understand […]
Survivorship Champions is a program for all clinicians and researchers, both oncology and primary care, who are interested in improving survivorship care and primary care’s role in caring for cancer survivors.
The NCCS Cancer Policy & Advocacy Team (CPAT) is a program for survivors and caregivers to learn about pressing policy issues that affect quality cancer care in order to be engaged as advocates in public policy around the needs of cancer survivors.
NCCS represents the millions of Americans who share a common experience – living with, through and beyond a cancer diagnosis. By sharing your story of how you have been touched by cancer, you are supporting the national cancer survivorship movement.
Together we can improve cancer care for survivors! Sign up to be the first to know about cancer policy issues and ways to take action
National Coalition for Cancer Survivorship
8455 Colesville Road | Suite 930 | Silver Spring, MD 20910
info@canceradvocacy.org | (877) NCCS-YES
Privacy Policy | Terms and Conditions
Copyright © 1995-2024 by the National Coalition for Cancer Survivorship
National Coalition for Cancer Survivorship, NCCS, Cancer Survival Toolbox, and related Logos are registered in the United States as trademarks of the National Coalition for Cancer Survivorship.
Your gift to NCCS helps build a brighter, more inclusive future
for cancer survivors everywhere.
Now through December 31 your gift to NCCS will be doubled!
Text NCCS to 24365
OR
"*" indicates required fields
"*" indicates required fields
Be the first to hear about cancer policy and survivorship issues! Subscribe and receive the biweekly NCCS Health Care Roundup, invites to webinars and events, and more.
Founder
Northeast Regional Cancer Institute
“Perhaps one of the most impactful collaborations in Dr. Brereton’s extraordinary career remains his early work and long friendship with Ellen Stovall. Through him, and in turn through the thousands of lives he has touched, Ellen’s work continues, and her mission lives on.”
—Karen M. Saunders
President, Northeast Regional Cancer Institute